Patents by Inventor Marijn Aletta GILLISSEN

Marijn Aletta GILLISSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS
    Publication number: 20230242667
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Application
    Filed: February 22, 2023
    Publication date: August 3, 2023
    Inventors: Hergen SPITS, Tim BEAUMONT, Marijn Aletta GILLISSEN, Adrianus Quirinus BAKKER, Mette Deborah HAZENBERG, Martijn KEDDE
  • AML ANTIGENS AND USES THEREOF
    Publication number: 20230235018
    Abstract: The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
    Type: Application
    Filed: October 27, 2022
    Publication date: July 27, 2023
    Inventors: Hergen SPITS, Marijn Aletta GILLISSEN, Martijn KEDDE, Mette Deborah HAZENBERG, Paula Maria Wilhelmina VAN HELDEN, Wouter POS
  • Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
    Patent number: 11629200
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: April 18, 2023
    Assignee: KLING BIOTHERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Marijn Aletta Gillissen, Adrianus Quirinus Bakker, Mette Deborah Hazenberg, Martijn Kedde
  • AML antigens and uses thereof
    Patent number: 11524989
    Abstract: The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: December 13, 2022
    Assignee: KLING BIOTHERAPEUTICS B.V.
    Inventors: Hergen Spits, Marijn Aletta Gillissen, Martijn Kedde, Mette Deborah Hazenberg, Paula Maria Wilhelmina van Helden, Wouter Pos
  • MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS
    Publication number: 20200239593
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 30, 2020
    Inventors: Hergen SPITS, Tim BEAUMONT, Marijn Aletta GILLISSEN, Adrianus Quirinus BAKKER, Mette Deborah HAZENBERG, Martijn KEDDE
  • Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
    Patent number: 10556963
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 11, 2020
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Marijn Aletta Gillissen, Adrianus Quirinus Bakker, Mette Deborah Hazenberg, Martijn Kedde
  • AML ANTIGENS AND USES THEREOF
    Publication number: 20180170998
    Abstract: The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 21, 2018
    Inventors: Hergen SPITS, Marijn Aletta GILLISSEN, Martijn KEDDE, Mette Deborah HAZENBERG, Paula Maria Wilhelmina van HELDEN, Wouter POS
  • MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS
    Publication number: 20160326261
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 10, 2016
    Inventors: Hergen SPITS, Tim BEAUMONT, Marijn Aletta GILLISSEN, Adrianus Quirinus BAKKER, Mette Deborah Hazenberg